Abstract 601P
Background
The multicohort KEYNOTE-158 (NCT02628067) trial supported the US FDA and EMA approval of pembrolizumab across multiple microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors. The incidence of MSI-H/dMMR advanced cancer in patients (pts) of Chinese descent is similar to that reported in Western populations (Liu et al 2019, Cancer Research 79:616). In cohort L of KEYNOTE-158, we evaluated the efficacy and safety of pembrolizumab in pts of Chinese descent with MSI-H/dMMR solid tumors.
Methods
In this nonrandomized, phase 2, open-label trial, pts aged ≥ 18 years of Chinese descent were enrolled. These pts had to have confirmed MSI-H/dMMR unresectable or metastatic cancers who had ≥1 prior lines of therapy. Eligible pts received 200 mg pembrolizumab Q3W for up to 35 cycles, until progression, unacceptable toxicity, or pt/investigator withdrawal. MSI-H/dMMR status was assessed centrally by PCR or ICH. The primary endpoint was ORR per RECIST 1.1 by independent central review. Secondary endpoints were DOR, PFS, OS and safety. The database cut-off date was July 26, 2022.
Results
At data cut-off, a total of 24 pts were enrolled of which 20 pts were for efficacy evaluation having at least 6 months (mo) of follow-up. The overall ORR was 70.0% (95% CI: 45.7%- 88.1%) for the 20 pts. The median DOR was not reached (NR) (range, 2.1+ - 19.3+) with a 12-mo DOR rate of 85.7%. Median PFS was NR (95% CI: 15.8-NR) with an 18-mo PFS rate of 68.0%. The median OS was NR (95% CI: 9.5, NR) with an 18-mo OS rate of 80.2%. Treatment-related adverse events (AE) were reported in 19 (79%) of the 24 pts enrolled. Grade ≥3 treatment-related AEs occurred in 4 (17%) pts with no grade 5 AEs. Immune-mediated AEs occurred in 8 pts (33%). Of these pts, 2 (8%) had grade 3 AEs (myositis or rash in 1 pt each). No grade 4 or 5 immune-mediated AEs occurred.
Conclusions
Pembrolizumab provided clinically meaningful antitumor activity and durable responses in pts of Chinese descent with MSI-H/dMMR tumors, with a manageable safety profile. No new safety signals were identified. These results are consistent with those reported for patients in the global population.
Clinical trial identification
NCT02628067; first posted December 9, 2015.
Editorial acknowledgement
Provided by Jose Casasnovas Nieves, PhD, an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Legal entity responsible for the study
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Funding
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Disclosure
M. Xu, N. Li, Y. Mao: Financial Interests, Personal, Full or part-time Employment: MSD China. A. Gozman: Financial Interests, Personal, Full or part-time Employment: Merck & Co., Inc.; Financial Interests, Personal, Stocks/Shares: Merck & Co., Inc. All other authors have declared no conflicts of interest.
Resources from the same session
425P - Engineered <italic>Lactococcus lactis</italic> as a personalized cancer vaccine platform induces antitumour immunity via membrane-inserted peptide for neoantigens
Presenter: Meng Zhu
Session: Poster Display
Resources:
Abstract
426P - Characterization of a novel comprehensive genomic profiling test with better detection of heterozygous deletions and gene fusions
Presenter: ryouta kakuta
Session: Poster Display
Resources:
Abstract
427P - Real-world performance of a comprehensive next-generation sequencing (NGS) panel for patients (pts) with solid tumors from Asia and the Middle East (AME)
Presenter: Nitesh Rohatgi
Session: Poster Display
Resources:
Abstract
428P - What do women want to see in a personalized breast cancer risk report? A qualitative study of Asian women of two countries
Presenter: Faustina Audrey Agatha
Session: Poster Display
Resources:
Abstract
429P - Clinical utility and outcomes of liquid biopsy-based next generation sequencing in identification of actionable genomic mutations in solid malignancy: A single center retrospective study in the Philippines
Presenter: Omar Maaño
Session: Poster Display
Resources:
Abstract
436P - Chemotherapy-induced hand-foot syndrome, comparative efficacy and safety of pharmacological prophylaxis: Systematic review and network meta-analysis
Presenter: Anand Srinivasan
Session: Poster Display
Resources:
Abstract
437P - A randomized single blinded phase II trial comparing efficacy and quality of life of topical aloe vera gel plus urea cream versus urea cream alone for prevention of hand-foot syndrome in cancer patients receiving capecitabine
Presenter: Lucksika Wanichtanom
Session: Poster Display
Resources:
Abstract
438P - A novel treatment for immune checkpoint inhibitor-related myocarditis
Presenter: Takahiro Niimura
Session: Poster Display
Resources:
Abstract
439P - Randomized controlled trial evaluating efficacy of topical urea-based cream for capecitabine-associated hand-foot syndrome prevention
Presenter: Concord Wongkraisri
Session: Poster Display
Resources:
Abstract
440P - Real-world adverse events of targeted therapy reported by pharmacist in oncology clinic
Presenter: TIKUMPORN PORNWISETSIRIKUL
Session: Poster Display
Resources:
Abstract